Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 52-Week High – What’s Next?

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $27.19 and last traded at $26.61, with a volume of 52586 shares changing hands. The stock had previously closed at $26.29.

Chugai Pharmaceutical Stock Performance

The stock has a market capitalization of $82.34 billion, a price-to-earnings ratio of 32.49 and a beta of 0.81. The firm has a fifty day moving average of $22.45 and a 200-day moving average of $22.94.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its earnings results on Thursday, January 30th. The company reported $0.18 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. On average, analysts predict that Chugai Pharmaceutical Co., Ltd. will post 0.74 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.